The closing price of Spruce Biosciences Inc (NASDAQ: SPRB) was $0.74 for the day, down -3.58% from the previous closing price of $0.76. On the day, 520649 shares were traded.
Ratios:
Our analysis of SPRB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.18 and its Current Ratio is at 4.18. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on March 14, 2024, Downgraded its rating to Sector Perform and sets its target price to $2 from $9 previously.
On March 14, 2024, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $9 to $2.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 21 ’24 when Novo Holdings A/S sold 465,021 shares for $0.75 per share. The transaction valued at 350,951 led to the insider holds 2,550,000 shares of the business.
Novo Holdings A/S sold 359,979 shares of SPRB for $264,081 on Mar 20 ’24. The 10% Owner now owns 3,015,021 shares after completing the transaction at $0.73 per share. On Mar 19 ’24, another insider, Novo Holdings A/S, who serves as the 10% Owner of the company, sold 593,000 shares for $0.76 each. As a result, the insider received 447,715 and left with 3,375,000 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.00 while its Price-to-Book (P/B) ratio in mrq is 0.39.
Stock Price History:
Over the past 52 weeks, SPRB has reached a high of $5.95, while it has fallen to a 52-week low of $0.68.
Shares Statistics:
A total of 41.03M shares are outstanding, with a floating share count of 22.16M. Insiders hold about 46.15% of the company’s shares, while institutions hold 36.72% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by SPRX analysts. The consensus estimate for the next quarter is $34.27, with high estimates of $9.02 and low estimates of $26.26.
